Johnson & Johnson (NYSE:JNJ) is a global leader in the healthcare sector, known for its diverse range of products in pharmaceuticals, medical devices, and consumer health. As JNJ prepares to release its quarterly earnings on January 21, 2026, analysts expect an earnings per share (EPS) of $2.49 and revenue of approximately $24.16 billion.
The company's pharmaceutical and MedTech sectors are driving its growth, with successful products like Darzalex, Tremfya, and Erleada. Despite challenges from declining Stelara sales and pressures in China, JNJ's MedTech division is performing well, especially in cardiovascular and surgical units. The Zacks Consensus Estimate aligns closely with Wall Street's projections, forecasting fourth-quarter sales at $24.14 billion and EPS at $2.50.
JNJ aims for over 5% revenue growth in 2026, despite slight declines in earnings estimates for 2025 and 2026. The 2025 estimate has decreased from $10.87 to $10.83 per share, while the 2026 estimate has dropped from $11.48 to $11.46 per share. These adjustments reflect the company's strategic planning amid market challenges.
Financially, JNJ maintains a strong position with a P/E ratio of 21.14, indicating investor confidence in its earnings potential. The price-to-sales ratio of 5.72 and enterprise value to sales ratio of 6.02 highlight the company's market valuation. Additionally, the enterprise value to operating cash flow ratio of 22.90 underscores its cash flow efficiency.
JNJ's debt-to-equity ratio of 0.58 shows a balanced approach to financing, while a current ratio of 1.07 indicates its capability to meet short-term obligations. With an earnings yield of 4.73%, JNJ offers a solid return on investment, reinforcing its status as a reliable player in the healthcare industry.
